Precision Epigenetics: Targeting The Epigenome To Treat Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,940,576.00
Summary
Epigenetic marks are changes made to the DNA that allow genes to be switched off in some cells and switched on in others. These marks are critical to normal development and often go wrong in disease. We aim to find genes that add epigenetic marks to the DNA and understand how they co-operate at the molecular level to switch genes off. Our focus is on one such gene, SMCHD1. We are developing new drugs against SMCHD1 to treat incurable neurodevelopmental disorder PWS and muscular dystrophy FSHD.
Mechanisms Of Cell Death Driven Inflammation In The Skin
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Inflammatory skin conditions are a leading cause of disease. Current therapies treat symptoms not causes of inflammation. Skin cells constantly interact with cells of the immune system, and with a diverse array of helpful and harmful microorganisms. My data suggest a role of the skin flora and resident immune cells in the initiation and progression of skin disease. I will investigate how the microbiota and immune cells can initiate cell death and drive excessive immune responses in the skin.
Understanding And Harnessing Immunity To Fight Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$3,138,220.00
Summary
Novel cancer therapies aimed at stimulating the body's immune defence have shown remarkable clinical success, although the immune mechanisms that can prevent disease recurrence remain poorly understood. Our study will fill this important gap in knowledge by elucidating the mechanisms of efficient immune protection from skin cancer and metastatic disease. As such, our results will be important for the development and improvement of innovative cancer therapies.
Deciphering Mechanisms Underlying Breast Cancer To Improve Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$3,314,215.00
Summary
Breast cancer is a highly heterogeneous disease. Patients are often treated in a ‘one size fits all’ approach, but response to therapy remains disparate. To more effectively personalise therapy, there is a pressing need to define the precise cell types and initiating genetic events that give rise to breast cancer. This application is centred on understanding mechanisms of breast cancer initiation and progression, with the potential of identifying new prognostic markers and therapeutic targets.